-
Sub-Journal of "Nature": Two "killer" viruses and cancer cells that threaten human health, who will die when the two meet?
Time of Update: 2021-09-06
Therefore, in the future, we can use laminin as a biomarker to classify cancer patients based on its expression level in order to predict the sensitivity and responsiveness of different types of cancer to H-1PV-based anti-cancer therapies .
-
Yan Ning's team "Nature" published an article revealing the mechanism of action of powerful painkillers
Time of Update: 2021-09-06
Today, "Nature" published an online paper by Professor Yan Ning's team, revealing the structure of the powerful painkiller ziconotide when combined with the human N-type voltage-gated calcium channel Cav2.
-
A head-to-head comparison study between basal insulin and GLP-1RA compound preparations and premixed insulin is released
Time of Update: 2021-09-06
"Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with iGlarLixi vs Premix 70/30 in the SoliMix Trial", Presentation 234-OR, American Diabetes Association (ADA ) 81st Scientific Sessions (virtual event), June 28, 2021.
-
Nuocheng Jianhua Obutinib was approved to carry out Phase II clinical studies for the treatment of MS in Poland and Ukraine
Time of Update: 2021-09-06
Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor obutinib for the treatment of multiple sclerosis (MS) clinical trial application (CTA) has been obtained by the Polish authorities and the Ukrainian Ministry of Health and With the approval of the ethics committee, phase II clinical studies will be launched in these two countries soon .
-
Rongchang Biological Vidicuzumab was identified as a breakthrough therapy for its indications
Time of Update: 2021-09-06
On June 29, the website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) showed that China’s first original antibody-conjugated drug (ADC) new drug,
-
Many diseases can be found by looking at the retina?
Time of Update: 2021-09-06
Researchers have not only shown in this study that the deep learning model can detect chronic kidney disease and type 2 diabetes by just "looking at" the photo of the retinal base .
-
Masks with nucleic acid biosensors embedded in wearable fabrics that can detect new coronaviruses in the air are coming
Time of Update: 2021-09-06
If there is a nucleic acid biosensor that can be embedded in fabrics, can it detect bacteria and viral pathogens in the air, including the new coronavirus?
The standard laboratory results are consistent, and it can also be embedded in a flexible matrix for real-time and dynamic monitoring of target pathogens .
-
Once a week!
Time of Update: 2021-09-06
Text | SunshineOn July 13, Sanofi's recombinant human coagulation factor VIII Fc-von Willebrand factor-XTEN fusion protein (efanesoctocog alfa, rFVIIIFc-VWF-XTEN, BIVV001) for injection was awarded CDE's proposed breakthrough therapy and its proposed indications It is used for adults and children with hemophilia A: (1) Routine preventive treatment to reduce the frequency of bleeding; (2) On-demand treatment of bleeding; (3) Treatment of perioperative bleeding .
-
Nature Sub-Journal: LINC00842 promotes the malignant progression of pancreatic cancer through metabolic remodeling
Time of Update: 2021-09-06
For example, lincRNAs can recruit transcription factors to regulate the expression of genes involved in metabolism; they can regulate post-translational modifications of metabolism-related proteins, or they can be used as scaffolds or decoys to promote the interaction between metabolic enzymes .
LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling.
-
RNAi combined immunotherapy innovative combination therapy for hepatitis B is about to start phase 2 clinical trials
Time of Update: 2021-09-06
Note: The original text has been deletedReference materials:[1] Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection.
-
Roche's Tecentriq treatment of non-small cell lung cancer submits a marketing application in Japan
Time of Update: 2021-09-06
Data show that in all randomized stage II-IIIA NSCLC patients, after surgery and chemotherapy, Tecentriq used in adjuvant therapy compared with Best Supportive Care (BSC), reducing the risk of disease recurrence or death by 21% ( Disease-free survival, PFS; HR=0.
-
Gastroenterology: Scientists may be able to predict whether colorectal cancer will respond to immunotherapy!
Time of Update: 2021-09-06
Recently, in a research report entitled "Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts" published in the international journal Gastroenterology, scientists from King’s College, University of London, UK, Research on colorectal cancer found that the level of specific immune cells may be the best predictor to help clarify whether immunotherapy is effective for patients with colorectal cancer .
-
The cancer-free survival period is two years long! Chinese innovative drug targeted adjuvant treatment of lung cancer
Time of Update: 2021-09-06
The EVIDENCE study showed that after radical surgery in patients with stage II-IIIA EGFR-mutant NSCLC, compared with standard adjuvant chemotherapy, adjuvant therapy with icotinib significantly prolonged disease-free survival (DFS) and was better tolerated .
-
The new crown is still there, what will the future look like
Time of Update: 2021-09-06
Taking into account the global scenarios that may arise in the future, the experts discussed in the article multiple correlations with future infection patterns (local or seasonal epidemics), the development of virus variants, potential changes in transmission patterns, and the impact on vaccine deployment.
-
Also on the safety risks of new anti-Alzheimer's drugs that cannot be ignored
Time of Update: 2021-09-06
In Alzheimer's disease, the precipitated protein in the patient's brain is originally a protein substance that is extremely difficult to remove .
-
New crown mutant strain "Lambda" attracts attention
Time of Update: 2021-09-06
According to a report on the 6th by the American Interest Science website, this new strain may have mutations that can enhance its transmission ability and is spreading in many countries around the world, attracting the attention of health officials in many countries .
-
Keytruda for the treatment of the second most common skin cancer expands its indications again
Time of Update: 2021-09-06
S. FDA has approved its anti-PD-1 antibody therapy Keytruda to expand its indications, a single-drug treatment for locally advanced cutaneous squamous cell carcinoma that cannot be cured by surgery or radiotherapy.
Retrieved July 6, 2021, from https:// indication-for-mercks-keytruda-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma-cscc/
-
Nature Sub-Journal: Plasma phosphorylated tau combined with other methods can predict Alzheimer's disease
Time of Update: 2021-09-06
On May 24, 2021, Oskar Hansson, Sebastian Palmqvist and other researchers from Lund University in Sweden jointly published an online publication entitled "Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures" in the journal Nature Medicine.
-
Cell: Revealing that neutrophil elastase selectively kills cancer cells and is expected to develop a new anti-cancer therapy
Time of Update: 2021-09-06
Through this new study, these authors determined that neutrophil elastase (ELANE) is a major anti-cancer protein released by human neutrophils, which specifically activates the cell death pathway in cancer cells .
-
Canadian researchers develop drugs to treat diabetic retinopathy
Time of Update: 2021-09-06
The antibody designed by the team activates the Frizzled4-LRP5 receptor complex, which successfully stimulates the Wnt signal in the blood-retinal barrier and effectively restores the barrier function .
The antibody restored the mouse's barrier function and corrected the formation of retinal blood vessels .
